// App-Quantinova.ai

BSH19‐PO‐086 : Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure

Researchers

Presenter

  • T. Munir

Principal Investigators

  • A. Rawstron

  • K. Brock

  • S. Munoz Vicente

  • F. Yates

  • R. Bishop

  • S. Cramp

  • R. DeTute

  • S. Dalal

  • N. Webster

  • D. Macdonald

  • A. Pettitt

  • S. Devereux

  • O. Sheehy

  • C. Fegan

  • C.P. Fox

  • A. Bloor

  • P. Hillmen

Medical Centers

  • St James's Institute of Oncology, Leeds Teaching Hospital

  • St James's institute of Oncology, Leeds

  • University of Birmingham, Institute of Cancer and Genomic Sciences, Cancer Research UK Clinical Trials Unit

  • University of Birmingham, Institute of Cancer and Genomic Sciences, Cancer Research UK Clinical Trials Unit

  • University of Birmingham, Institute of Cancer and Genomic Sciences, Cancer Research UK Clinical Trials Unit

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Haematology Malignancy Diagnostic Service, St James's institute of Oncology

  • Haematology Malignancy Diagnostic Service, St James's institute of Oncology, Leeds Teaching Hospital, Leeds

  • Imperial College Healthcare NHS Trust, London,

  • Haematology, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Belfast HSC Trust, Belfast

  • Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff

  • Nottingham University Hospitals NHS Trust, Nottingham,

  • The Christie NHS Foundation Trust, Manchester,

  • Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • ISRCTN12695354

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved